User profiles for "author:S Moran"
Sebastián MoránCancer Epigenetics and Biology Program (PEBC); Bellvitge Biomedical Research Institute … Verified email at idibell.cat Cited by 11680 |
Marginal zone B cells
S Pillai, A Cariappa, ST Moran - Annu. Rev. Immunol., 2005 - annualreviews.org
▪ Abstract Our views regarding the origins and functions of splenic marginal zone B cells
have changed considerably over the past few years. Perspectives regarding the …
have changed considerably over the past few years. Perspectives regarding the …
Validation of a DNA methylation microarray for 850,000 CpG sites of the human genome enriched in enhancer sequences
S Moran, C Arribas, M Esteller - Epigenomics, 2016 - Future Medicine
Aim: DNA methylation is the best known epigenetic mark. Cancer and other pathologies
show an altered DNA methylome. However, delivering complete DNA methylation maps is …
show an altered DNA methylome. However, delivering complete DNA methylation maps is …
Chronology of late Wisconsinan glaciation in middle North America
L Clayton, SR Moran - Quaternary Science Reviews, 1982 - Elsevier
We propose a chronology of late Wisconsinan glacial fluctuations in middle North America,
from Alberta to Wisconsin, based on radiocarbon dates derived solely from wood. Previous …
from Alberta to Wisconsin, based on radiocarbon dates derived solely from wood. Previous …
The soil moisture active passive (SMAP) mission
…, KC McDonald, M Moghaddam, S Moran… - Proceedings of the …, 2010 - ieeexplore.ieee.org
The Soil Moisture Active Passive (SMAP) mission is one of the first Earth observation
satellites being developed by NASA in response to the National Research Council's …
satellites being developed by NASA in response to the National Research Council's …
[PDF][PDF] A landscape of pharmacogenomic interactions in cancer
…, L Richardson, J Wang, T Zhang, S Moran… - Cell, 2016 - cell.com
Systematic studies of cancer genomes have provided unprecedented insights into the
molecular nature of cancer. Using this information to guide the development and application …
molecular nature of cancer. Using this information to guide the development and application …
[HTML][HTML] Mop3 is an essential component of the master circadian pacemaker in mammals
MK Bunger, LD Wilsbacher, SM Moran, C Clendenin… - Cell, 2000 - cell.com
Circadian oscillations in mammalian physiology and behavior are regulated by an
endogenous biological clock. Here we show that loss of the PAS protein MOP3 (also known …
endogenous biological clock. Here we show that loss of the PAS protein MOP3 (also known …
[BOOK][B] Managing cultural differences
RT Moran, PR Harris, S Moran - 2010 - taylorfrancis.com
The international nature of modern Business means that individual and organizational
success is no longer dependent solely on business acumen-our ability to understand …
success is no longer dependent solely on business acumen-our ability to understand …
Distinct DNA methylomes of newborns and centenarians
Human aging cannot be fully understood in terms of the constrained genetic setting.
Epigenetic drift is an alternative means of explaining age-associated alterations. To address …
Epigenetic drift is an alternative means of explaining age-associated alterations. To address …
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a …
…, HS Soifer, SP Shepherd, S Moran… - The Lancet …, 2021 - thelancet.com
Background Treatment options are sparse for patients with advanced cholangiocarcinoma
after progression on first-line gemcitabine-based therapy. FGFR2 fusions or rearrangements …
after progression on first-line gemcitabine-based therapy. FGFR2 fusions or rearrangements …
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled …
…, JS Link, AA Joy, R Bryce, A Wong, S Moran… - The lancet …, 2017 - thelancet.com
Background ExteNET showed that 1 year of neratinib, an irreversible pan-HER tyrosine
kinase inhibitor, significantly improves 2-year invasive disease-free survival after …
kinase inhibitor, significantly improves 2-year invasive disease-free survival after …